{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:15Z","timestamp":1740144135886,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-024-08429-7","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T11:02:21Z","timestamp":1725534141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Junlan","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongling","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiying","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-1689","authenticated-orcid":false,"given":"Ertao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"issue":"1","key":"8429_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65\u201370.","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"8429_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2020.05.089","volume":"84","author":"AB Gottlieb","year":"2021","unstructured":"Gottlieb AB, Merola JF. Axial psoriatic arthritis: an update for dermatologists. J Am Acad Dermatol. 2021;84(1):92\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"8429_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/1744666X.2019.1573675","volume":"15","author":"M Harth","year":"2019","unstructured":"Harth M, Nielson WR. Pain and affective distress in arthritis: relationship to immunity and inflammation. Expert Rev Clin Immunol. 2019;15(5):541\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"8429_CR4","doi-asserted-by":"publisher","first-page":"adv00160","DOI":"10.2340\/00015555-3510","volume":"100","author":"S Bylund","year":"2020","unstructured":"Bylund S, Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"8429_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"3\u20134","key":"8429_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/jocn.15577","volume":"30","author":"CF Pollo","year":"2021","unstructured":"Pollo CF, Miot HA, Matos TDS, de Souza JM, Jorge MFS, Miot LDB, et al. Prevalence and factors associated with depression and anxiety in patients with psoriasis. J Clin Nurs. 2021;30(3\u20134):572\u201380.","journal-title":"J Clin Nurs"},{"issue":"12","key":"8429_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1080\/13696998.2019.1638788","volume":"22","author":"Q Cai","year":"2019","unstructured":"Cai Q, Teeple A, Wu B, Muser E. Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasis. J Med Econ. 2019;22(12):1290\u20137.","journal-title":"J Med Econ"},{"issue":"4","key":"8429_CR8","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.3390\/ijerph19042060","volume":"19","author":"M Fabrazzo","year":"2022","unstructured":"Fabrazzo M, Romano F, Arrigo M, Puca RV, Fuschillo A, De Santis V, et al. A multivariate analysis of depression prevalence in psoriasis patients: a cohort study. Int J Environ Res Public Health. 2022;19(4):2060.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"8429_CR9","doi-asserted-by":"publisher","first-page":"adv00422","DOI":"10.2340\/00015555-3712","volume":"101","author":"M Talamonti","year":"2021","unstructured":"Talamonti M, Malara G, Natalini Y, Bardazzi F, Conti A, Chiricozzi A, et al. Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study. Acta Derm Venereol. 2021;101(3):adv00422.","journal-title":"Acta Derm Venereol."},{"issue":"6","key":"8429_CR10","first-page":"890","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8429_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13075-017-1265-5","volume":"19","author":"M Bergman","year":"2017","unstructured":"Bergman M, Lundholm A. Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis. Arthritis Res Ther. 2017;19(1):63.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"8429_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3109\/14397595.2015.1136726","volume":"26","author":"KW Hagberg","year":"2016","unstructured":"Hagberg KW, Li L, Peng M, Shah K, Paris M, Jick S. Incidence rates of suicidal behaviors and treated depression in patients with and without psoriatic arthritis using the Clinical Practice Research Datalink. Mod Rheumatol. 2016;26(5):774\u20139.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"8429_CR13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/jdv.14175","volume":"31","author":"JJ Wu","year":"2017","unstructured":"Wu JJ, Penfold RB, Primatesta P, Fox TK, Stewart C, Reddy SP, et al. The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol. 2017;31(7):1168\u201375.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"8429_CR14","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.semarthrit.2020.02.001","volume":"50","author":"EZ Zusman","year":"2020","unstructured":"Zusman EZ, Howren AM, Park JYE, Dutz J, De Vera MA. Epidemiology of depression and anxiety in patients with psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(6):1481\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"8429_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.reuma.2010.03.003","volume":"7","author":"M Freire","year":"2011","unstructured":"Freire M, Rodr\u00edguez J, M\u00f6ller I, Valc\u00e1rcel A, Tornero C, D\u00edaz G, et al. Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Reumatol Clin. 2011;7(1):20\u20136.","journal-title":"Reumatol Clin"},{"issue":"10188","key":"8429_CR16","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303\u201311.","journal-title":"Lancet"},{"issue":"10","key":"8429_CR17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed MF, Chen S, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72(10):1607\u201320.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"8429_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80(3):312\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8429_CR19","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s40744-021-00379-9","volume":"8","author":"V Strand","year":"2021","unstructured":"Strand V, Mease PJ, Soriano ER, Kishimoto M, Salvarani C, Saffore CD, et al. Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from SELECT-PsA 1. Rheumatol Ther. 2021;8(4):1789\u2013808.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"8429_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3899\/jrheum.110845","volume":"39","author":"W Tillett","year":"2012","unstructured":"Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, et al. The ClASsification for Psoriatic ARthritis (CASPAR) criteria\u2013a retrospective feasibility, sensitivity, and specificity study. J Rheumatol. 2012;39(1):154\u20136.","journal-title":"J Rheumatol"},{"key":"8429_CR21","doi-asserted-by":"publisher","first-page":"111512","DOI":"10.1016\/j.jpsychores.2023.111512","volume":"175","author":"B Ristic","year":"2023","unstructured":"Ristic B, Carletto A, Fracassi E, Pacenza G, Zanetti G, Pistillo F, et al. Comparison and potential determinants of health-related quality of life among rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: a cross-sectional study. J Psychosom Res. 2023;175:111512.","journal-title":"J Psychosom Res"},{"issue":"10","key":"8429_CR22","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279\u201389.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"8429_CR23","doi-asserted-by":"publisher","first-page":"e001838","DOI":"10.1136\/rmdopen-2021-001838","volume":"7","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Pacheco-Tena C, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021;7(3):e001838.","journal-title":"RMD Open"},{"issue":"2","key":"8429_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56(2):476\u201388.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"8429_CR25","first-page":"1219","volume":"13","author":"TL Timis","year":"2023","unstructured":"Timis TL, Beni L, Mocan T, Florian IA, Orasan RI. Biologic Therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients. Life (Basel). 2023;13(5):1219.","journal-title":"Life (Basel)"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08429-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08429-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08429-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T11:05:03Z","timestamp":1725534303000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08429-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8429"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08429-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is approved by the Institutional Medical Ethics Committee of Shenzhen Traditional Chinese Medicine Hospital (approval number: K2023-122\u201302). All subjects are required to sign the written informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Model consent form has given to participants and authorized surrogates.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"590"}}